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ABSTRACT
Colon cancer liver metastasis is often the lethal aspect of this disease. Well-
isolated metastases are candidates for surgical resection, but recurrence is common. 
Better adjuvant treatment is therefore needed to reduce or prevent recurrence. In 
the present study, HT-29 human colon cancer cells expressing red fluorescent protein 
(RFP) were used to establish liver metastases in nude mice. Mice with a single liver 
metastasis were randomized into bright-light surgery (BLS) or the combination of BLS 
and adjuvant treatment with tumor-targeting S. typhimurium A1-R. Residual tumor 
fluorescence after BLS was clearly visualized at high magnification by fluorescence 
imaging. Adjuvant treatment with S. typhimurium A1-R was highly effective to 
increase survival and disease-free survival after BLS of liver metastasis. The results 
suggest the future clinical potential of adjuvant S. typhimurium A1-R treatment after 
liver metastasis resection.
INTRODUCTION
Colon cancer liver metastasis is often the lethal 
aspect of this disease [1]. Well-isolated metastases 
are candidates for surgical resection, but recurrence is 
common [2]. Better adjuvant treatment is therefore needed 
to reduce or prevent recurrence. 
Bacterial therapy of cancer has a long history [3-5]. 
The bacteria, now known as Streptococcus pyogenes [3-5], 
was found in cancer patients who had remission and was 
used for therapy in the late 19th and early 20th centuries [3-
5], especially under William B. Coley. 
Hoption Cann et al. [5] compared patient outcome 
with early bacterial treatment to modern chemotherapy 
and found the 10-year survival rates were comparable 
[5]. Beginning in the middle of the last century, bacteria 
were used for cancer therapy in animal models [6-18]. 
Bifidobacterium [18] and Clostridium [19], obligate 
anaerobes which replicate only in necrotic areas of 
tumors, had anti-tumor efficacy in mouse tumor models. 
Spores of Clostridium novyi, without its lethal toxin (C. 
novyi no toxin [NT]), were recently used in a patient with 
leiomyosarcoma causing a metastatic lesion to regress 
after intratumor administration [20]. 
Salmonella typhimurium (S. typhimurium) is 
a facultative anaerobe, which in contrast to obligate 
anaerobes, allows growth in the viable regions as well 
as necrotic regions of tumors [20]. S. typhimurium-
VNP20009, with msbB and purI mutations, was found 
safe in a Phase I clinical trial of metastatic melanoma and 
renal carcinoma [21]. 
The tumor-targeting S. typhimurium A1-R strain 
developed by our laboratory has higher tumor colonization 
efficacy and antitumor efficacy than S. typhimurium-
VNP20009 [22], possibly because it has fewer attenuation 
mutations. S. typhimurium A1-R is auxotrophic for Leu-
-Arg, which prevents it from mounting a continuous 
infection in normal tissues. S. typhimurium A1-R was able 
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to inhibit or eradicate primary and metastatic tumors as 
monotherapy in nude mouse models of prostate [23, 24], 
breast [25-27], lung [28, 29], pancreatic [30-34], ovarian 
[35, 36] stomach [37], and cervical cancer [38], as well 
as sarcoma [39-41] and glioma [42,43], all of which are 
highly aggressive tumor models.
The present report demonstrates adjuvant treatment 
efficacy of S. typhimurium A1-R after bright-light surgery 
(BLS) of liver metastasis.
RESULTS AND DISCUSSION
BLS cannot resect the entire liver metastasis
Residual tumor fluorescence was detected on the 
surgical resection bed after BLS of HT-29-RFP liver 
metastasis (Figure 1). There was no significant difference 
in residual tumor area between the control group (0.237 ± 
0.094 mm2) and BLS group (0.250 ± 0.120 mm2). 
Adjuvant treatment with S. typhimurium A1-R 
increases survival after BLS
Adjuvant S. typhimurium A1-R treatment after BLS 
significantly prolonged both disease-free (P = 0.005; 
Figure 2A) and overall survival (P = 0.010; Figure 2B).
Liver metastasis of colon cancer is the major 
lethal event of this disease. In many cases, diffuse 
liver metastasis is inoperable. However, isolated liver 
metastasis provides an opportunity for resection, but 
BLS very often results in residual cancer cells. The 
present report demonstrates that S. typhimurium A1-R 
can eradicate sufficient residual cancer cells after BLS 
to significantly increase disease-free survival and overall 
survival. Future experiments will also use S. typhimurium 
A1-R as neoadjuvant chemotherapy to convert inoperable 
tumors to those that are resectable.
In a recent study, we found that Salmonella 
typhimurium A1-R was active as monotherapy on liver 
metastasis in the orthotopic HT-29 mouse model. The 
results of that study demonstrated the potential of S. 
typhimurium A1-R targeting of liver metastasis [44]. 
The recurrence rate after liver metastasis resection 
is high, up to 75% [1, 2, 45]. Adjuvant therapy for colon 
cancer liver metastasis is usually based on 5-fluorouracil 
and oxaliplatin and it is not highly effective [1, 2, 45]. 
Therefore, novel approaches are necessary to improve 
adjuvant therapy of colon cancer liver metastasis. 
The present study indicated that S. typhimuirum 
A1-R can be curative as adjuvant treatment for liver 
metastasis. Clinical trials of S. typhimurium A1-R for 
adjuvant therapy of patients with liver metastasis resection 
would have high potential. 
Previously developed concepts and strategies 
of highly selective tumor targeting [46-51] can take 
advantage of bacterial targeting of tumors, including 
tissue-selective therapy which focuses on unique properties 
of normal and tumor tissues [46, 51]. S. typhimurium 
A1-R can possibly overcome de-differentiation of a tumor 
leading to resistance to targeted chemotherapy, where the 
targeted protein or pathway may no longer be expressed 
[51], since S. typhimurium A1-R does not depend on 
Figure 1: Efficacy of BLS alone on liver metastasis. A. Tumor fluorescence was clearly detected before BLS. B. Tumor fluorescence 
still remained on the surgical resection bed (arrows) after BLS. C. Schematic diagram of the experimental design for adjuvant S. typhimurium 
A1-R treatment. Twelve mice were randomized into observation (n=6) and adjuvant groups (n=6). BF=bright field.
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such targets [46, 48]. S. typhimurium A1-R may also 
be effectively combined with teratogens which could 
selectively affect cancer cells that are dedifferentiated 
[47]. Since S. typhimurium A1-R can decoy quiescent 
cancer cells to begin to cycle, S. typhimurium A1-R could 
be effectively combined with agents which selectively 
target proliferating cancer cells [49], where normal cells 
are protected by agents which induce wild type p53 [50]. 
MATERIALS AND METHODS
Mice
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4–6 weeks old, were used in this study. 
All animal studies were conducted with an AntiCancer 
Institutional Animal Care and Use Committee (IACUC)-
protocol specifically approved for this study and in 
accordance with the principals and procedures outlined in 
the National Institute of Health Guide for the Care and 
Use of Animals under Assurance Number A3873-1. In 
order to minimize any suffering of the animals, anesthesia 
and analgesics were used for all surgical experiments. 
Animals were anesthetized by subcutaneous injection 
of a 0.02 ml solution of 20 mg/kg ketamine, 15.2 mg/
kg xylazine, and 0.48 mg/kg acepromazine maleate. The 
response of animals during surgery was monitored to 
ensure adequate depth of anesthesia. The animals were 
observed on a daily basis and humanely sacrificed by CO2 
inhalation when they met the following humane endpoint 
criteria: prostration, significant body weight loss, difficulty 
breathing, rotational motion and body temperature 
drop. The use of animals was necessary to evaluate S. 
typhimurium A1-R efficacy in vivo. Animals were housed 
with no more than 5 per cage. Animals were housed in a 
barrier facility on a high efficiency particulate arrestance 
(HEPA)-filtered rack under standard conditions of 12-hour 
light/dark cycles. The animals were fed an autoclaved 
laboratory rodent diet.  
Cell line 
The human colon cancer cell line HT-29, [52, 53] 
was maintained in DMEM (Irvine Scientific, Irvine, CA) 
supplemented with heat-inactivated 10% fetal bovine 
serum (FBS) (Gemini Biologic Products, Calabasas, 
CA), 2 mM glutamine, 100 units/ml penicillin, 100 μg/
ml streptomycin, and 0.25 μg/ml amphotericin B (Life 
Technologies, Inc., Grand Island, NY). The cells were 
incubated at 37°C in 5% CO2.
Establishment of RFP-labeled HT29 
The pDsRed-2 vector (Clontech Laboratories 
Inc., Palo Alto, CA) expressing RFP and the neomycin-
resistance gene was used to stably transfect HT-29 cells 
to express RFP. For RFP gene transfection, 25% confluent 
HT-29 cells were incubated with a mixture of retroviral 
Figure 2: Efficacy of adjuvant S. typhimurium A1-R treatment on disease-free and overall survival according to the 
Kaplan-Meier method. Mice in the adjuvant group had reduced recurrence (A) and increased survival (B) compared to those in the 
untreated control group.
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supernatants of PT67-RFP packaging cells and DMEM 
for 24 h. Fresh medium was replenished at this time, and 
cells were allowed to grow in the absence of retrovirus 
for 12 h. This procedure was repeated until high levels of 
RFP expression were achieved. Cells were then harvested 
with trypsin-EDTA and subcultured into selective medium 
that contained G418 (200 µg/ml) (Geneticin, Invitrogen 
Corp., Carlsbad, CA). The level of G418 was increased 
to 2,000 µg/ml stepwise. Clones expressing high levels 
of RFP were isolated and were amplified and transferred 
using conventional culture methods. High RFP-expression 
clones were isolated in the absence of G418 for 10 
passages to select for stable expression of RFP [52, 54, 
55].
Preparation of S. typhimurium A1-R
GFP-expressing S. typhimurium A1-R bacteria 
(AntiCancer Inc.) were grown overnight on LB medium 
(Fisher Sci., Hanover Park, IL, USA) and then diluted 1:10 
in LB medium. Bacteria were harvested at late-log phase, 
washed with PBS, and then diluted in PBS [23].
Initial establishment of liver metastases 
HT-29-RFP cells were harvested by trypsinization 
and washed twice with serum-free medium. Cells (5×105 
in 50 μl serum-free medium with 50% Matrigel) were 
injected into the superior and inferior pole of the spleen in 
mice. Three weeks after injection, liver metastases were 
established.
Surgical orthotopic implantation of liver 
metastasis 
Established liver metastases were resected and 
cut into blocks (3 mm3). A single tumor fragment was 
orthotopically implanted into the left lobe of the liver in 
other nude mice. Four weeks later, liver metastasis was 
observed in the implanted site.
Efficacy for adjuvant S. typhimurium A1-R 
treatment on liver metastasis after resection
Four weeks after orthotopic implantation to the 
liver, the liver metastasis was resected along the tumor 
margin under bright light. Twelve mice treated with 
standard bright-light surgery (BLS) were randomized into 
2 groups: a control group (n=6) and an S. typhimurium 
A1-R adjuvant group (n=6). S. typhimurium A1-R (5 × 
107 CFU/body, iv, weekly, 3 weeks) was administered to 
the mice as adjuvant treatment beginning one week after 
BLS. Tumor fluorescence was visualized with the OV100 
variable magnification small animal fluorescence imaging 
system  (Olympus Corp., Tokyo, Japan) before and right 
after BLS. Recurrence was monitored by weekly non-
invasive tumor fluorescence evaluation with the LT-9900 
Illumatool (Lightools Research, Encinitas, CA, USA) until 
the end of the experiment.
Statistical analysis 
SPSS statistics (version 21.0) was used for all 
statistical analyses (IBM, New York City, NY, USA). 
Survival curves were constructed using the Kaplan–
Meier method and compared using the log-rank test. A 
probability value of P < 0.05 was considered statistically 
significant.
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